Global Europe CRISPR Technology Market Size, Share and Trends Analysis
Europe CRISPR Technology Market valued at USD 0.85B in 2023, projected to reach USD 3.11B by 2032 at 15.5% CAGR.
$0.8B
$3.1B
15.5%
North America
Executive Summary
The European CRISPR technology market was valued at approximately USD 0.85 billion in 2023 and is projected to reach USD 3.11 billion by 2032, growing at a 15.5% CAGR. Key growth drivers include rising R&D investments in gene therapies, supportive EU regulatory frameworks, and expanding clinical trials. Germany, the UK, and France lead regional adoption. CRISPR Therapeutics AG is the dominant European player, with increasing competition from Editas Medicine and Intellia Therapeutics.
Key Highlights
Europe CRISPR market projected to reach USD 3.11B by 2032 at 15.5% CAGR from USD 0.85B in 2023.
CRISPR kits and reagents dominate with 45% market share; therapeutics segment grows fastest.
Germany leads European adoption driven by robust biotech infrastructure and R&D funding.
Market Overview
Market Context
Europe represents a significant share of the global CRISPR technology market, supported by strong academic research institutions, favorable funding mechanisms, and an evolving regulatory environment. Germany, the UK, and France serve as primary growth engines. The market spans therapeutics, agricultural biotechnology, and industrial applications, with clinical therapeutics emerging as the fastest-growing segment driven by CASGEVY approval.
Europe holds approximately 30% of the global CRISPR technology market, driven by strong biotech ecosystems in Germany, the UK, and France. The market is experiencing rapid growth due to expanding therapeutic pipelines and increasing adoption of CRISPR tools in drug discovery and agricultural biotechnology.
Market Stage
High growth
Adoption Level
Growing
Key Trends
Market Forecast & Data
Base Year (2023)
$0.8B
Forecast (2032)
$3.1B
CAGR (2024-2032)
15.5%
| Year | Market size ($ Billion) |
|---|---|
| 2023Base year | $0.85B |
| 2024 | $0.98B |
| 2025 | $1.13B |
| 2026 | $1.31B |
| 2027 | $1.51B |
| 2028 | $1.75B |
| 2029 | $2.02B |
| 2030 | $2.33B |
| 2031 | $2.69B |
| 2032 | $3.11B |
The European CRISPR market is forecast to grow from USD 0.85B to USD 3.11B by 2032 at a 15.5% CAGR. Growth is primarily driven by expanding clinical trials, increasing therapeutic approvals, and rising agricultural biotech applications. In vivo gene editing and base editing technologies represent the highest future revenue potential.
| Region | Market share | Growth rate | Largest market |
|---|---|---|---|
| North America | 40.0% | 16.2% | United States |
| Europe | 30.0% | 15.5% | Germany |
| Asia Pacific | 30.0% | 18.3% | China |
North America
#1Largest market: United States
Europe
#2Largest market: Germany
Market Dynamics
- Rising prevalence of genetic disorders driving therapeutic demand
- Increased EU funding for gene-editing research initiatives
- Expanding CRISPR applications beyond therapeutics into agriculture
Market Segmentation
| Segment | Share |
|---|---|
| Drug Discovery & DevelopmentLargest application segment supported by European pharma R&D investments. | 35.0% |
| Clinical TherapeuticsGrowing segment driven by approved CRISPR therapies and pipeline expansion. | 30.0% |
| Agriculture & FoodIncreasing gene-edited crop development under EU regulatory evolution. | 20.0% |
| Industrial BiotechnologyBiofuel and enzyme engineering applications gaining commercial traction. | 15.0% |
| Total | 100.0% |
| Segment | Share |
|---|---|
| CRISPR Kits & ReagentsDominant segment driven by widespread research and diagnostic applications across European labs. | 45.0% |
| CRISPR TherapeuticsFastest-growing segment fueled by CASGEVY approval and expanding clinical pipelines. | 30.0% |
| CRISPR ServicesCustom gene-editing services for pharma and biotech companies gaining traction. | 25.0% |
| Total | 100.0% |
By End User
- Pharmaceutical & Biotechnology Companies
- Academic & Research Institutes
- Contract Research Organizations (CROs)
Regional Analysis
North America
Lead: United StatesLargest market driven by FDA approvals, extensive clinical trials, and major company headquarters.
Europe
Lead: GermanySecond-largest market with strong biotech hubs in Germany, UK, and France; EU regulatory frameworks shaping growth.
Asia Pacific
Lead: ChinaFastest-growing region driven by government investments in gene editing and expanding biotech infrastructure.
Country-Level Analysis
| Country | Share | Growth |
|---|---|---|
| United States | 38.0% | +16.0% |
| Germany | 18.0% | +15.8% |
| China | 15.0% | +19.0% |
Competitive Landscape
CRISPR Therapeutics AG
Switzerland
Pioneer of approved CRISPR therapy CASGEVY; strong oncology and hemoglobinopathy pipeline across European clinical sites.
Swiss-US biotech leader pioneering CRISPR-based therapies with the first approved CRISPR therapy CASGEVY for sickle cell disease and beta-thalassemia.
Editas Medicine
United States
Clinical-stage company advancing in vivo and ex vivo editing with Cas12a platform; BRILLIANCE trial showed 79% vision improvement in LCA10 patients.
Clinical-stage gene editing company leveraging CRISPR Cas12a and Cas9 systems to develop transformative genomic medicines for serious diseases.
Intellia Therapeutics
United States
Leading in vivo gene editing with nexiguran ziclumeran for ATTR amyloidosis; Phase 3 MAGNITUDE-2 trial underway with European sites.
Leading in vivo CRISPR therapeutics developer advancing liver-targeted and oncology gene-editing programs with proprietary LNP delivery technology.
Recent Developments
Expanded CASGEVY commercial launch across 12 EU member states with new manufacturing partnerships
Initiated Phase 3 MAGNITUDE-2 trial for nexiguran ziclumeran at European clinical sites
Acquired Mirus Bio to strengthen CRISPR delivery technology portfolio in Europe
Regulatory Landscape
Research Methodology
Primary research
- Expert interviews with European biotech executives
- Surveys of clinical researchers and biotech firms
Secondary research
- Industry analyst reports
- Company financial filings
- EU regulatory databases
- Clinical trial registries
Validation: Triangulation method cross-referencing primary interviews, secondary sources, and regulatory filings
Strategic Takeaways
Europe's CRISPR market offers strong growth potential with 15.5% CAGR; prioritize companies with EU clinical trial approvals.
Expand CRISPR service offerings in Germany and UK to capture growing demand from pharma and academic clients.
Evolving EU GMO regulations will significantly impact agricultural CRISPR adoption timelines.
Frequently Asked Questions
Related research
Reports in the same field, each with its base-year figure and the growth rate it is published at.
- BiotechnologyGlobal Asia Pacific CRISPR Technology Market$1.2B · 16.5% CAGR
- BiotechnologyGlobal CRISPR Technology Market$2.7B · 14.5% CAGR
- BiotechnologyGlobal North America CRISPR Technology Market$3.1B · 14.2% CAGR
- BiotechnologyGlobal United States CRISPR Technology Market$4.2B · 17% CAGR
- BiotechnologyGlobal Europe Gene Therapy Market$1.4B · 20% CAGR
- BiotechnologyEurope Cell & Gene Therapy Manufacturing Market$1.8B · 13.5% CAGR